Delivery Order SPE2DB20D3103-SPE2DB21FQ2G4

Award Date 9/10/21
Potential Completion Date 9/13/21
Potential Value $4.3K
Ultimate Awardee
Cencora, Inc.
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of Insulin Aspart 100 Unit/ML VL 10ML. The contract has a firm fixed price of $4,746.50 and a completion date of January 19, 2024. The award is associated with a larger $999,999,999.00 Indefinite Delivery Contract (IDC) between Amerisourcebergen's parent company, Cencora, Inc., and the DLA Troop Support Medical division. This IDC serves...
This federal contract award, valued at $2,371.57, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of INSULIN ASPART 100 UNIT/ML PEN 3ML, a critical medical product. The contract is a Firm Fixed Price Delivery Order with a completion date of January 8, 2025. This award is part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA...
This federal contract award, valued at $16,257.40, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order, with a Firm Fixed Price pricing type, and covers the supply of INSULIN ASPART 100 UNIT/ML PEN 3ML medical products. The award is associated with a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA Troop Support Medical, valued...
This is a firm-fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $4,433.76, is for the delivery of INSULIN ASPART 100 UNIT/ML PEN 3ML. This order is part of a larger Indefinite Delivery Contract (IDC) worth $999,999,999 held by AmerisourceBergen with the DLA Troop Support Medical, which provides a comprehensive range of pharmaceutical products and...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of INSULIN ASPART 100 UNIT/ML PEN 3ML, a medical product used for diabetes management. The contract has a ceiling value of $41,682.05 and a period of performance through November 21, 2023. This contract is a firm fixed price delivery order issued under...
This federal contract award, with a ceiling value of $26,133.17, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is for the delivery of INSULIN ASPART 100 UNIT/ML PEN 3ML medical supplies, with a performance period ending on January 17, 2024. This contract is a Delivery Order, with a Firm Fixed Price pricing type, and is not designated with any set-aside requirements, indicating...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $14,610.83 firm fixed-price delivery order is for the supply of INSULIN ASPART 100 UNIT/ML PEN 3ML medical products. The contract has an ultimate completion date of December 26, 2023. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
This federal contract award, valued at $13,645.13, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract covers the delivery of 4563225373 INSULIN ASPART 100 UNIT/ML PEN 3ML, with a completion date of January 4, 2024. The contract is a delivery order under a larger Indefinite Delivery Contract (IDC) held by Cencora, Inc. with the DLA Troop Support Medical, valued at up to...
This is a federal delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $9,245.58, is for the supply of Insulin Aspart 100 Unit/mL Pen 3mL. The contract is a Firm Fixed Price type and has an ultimate completion date of December 18, 2023. This order is part of a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA...
This federal contract award is for the delivery of INSULIN ASPART 100 UNIT/ML PEN 3ML to the Medical Supply Chain, a component of the Defense Logistics Agency (DLA). The contract was awarded to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc., and has a ceiling value of $12,160.25. The contract is a delivery order under an Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running...
  • SPE2DB20D3103
    Indefinite Delivery Contract
  • SPE2DB20D3103-SPE2DB21FQ2G4
    Delivery Order

The federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of INSULIN ASPART 100 UNIT/ML PEN 3ML. The $4,266.80 Firm Fixed Price contract has an ultimate completion date of September 13, 2021.

This award is part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen's parent company, Cencora, Inc., and the DLA Troop Support Medical, valued at up to $999,999,999.00 through November 2026. The IDC serves as a primary vehicle for Cencora, Inc. to provide a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract does not have a set-aside designation, indicating open competition.

Generated 2/27/25, 12:48 PM